SA PRO
Free Account
Entrada Therapeutics, Inc.TRDANASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 80% recommend buying.

Consensus Rating
Buy
5 analysts·Limited coverage
80%
Rating Distribution
Strong Buy
00%
Buy
480%
Hold
120%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 43% higher.

Bear Case
$13.00
+9%
Consensus
$17.00
+43%
Bull Case
$21.00
+77%
Price Range5 analysts
Low
Consensus
High
$13.00
$21.00
Current Target
Current Price
$11.88
Upside to Target
$5.12

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-4.19(4 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+10.24%
EPS—
FY2028
Rev+210.18%
EPS—
FY2029
Rev-23.26%
EPS—

Earnings Surprises

Beat rate:67%(8/12 quarters)
Avg surprise:+109.9%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 28, 2026Oppenheimer
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Target:$21.00
+90.9%from $11.00
Nov 6, 2025Roth Capital
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
Target:$13.00
+87.1%from $6.95
Feb 28, 2025Roth Capital
Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM
Target:$23.00
+92.6%from $11.94
Nov 6, 2024H.C. Wainwright
Entrada Therapeutics (TRDA) PT Raised to $20 at H.C. Wainwright
Target:$20.00
+11.0%from $18.02
Jun 25, 2024H.C. Wainwright
Entrada Therapeutics price target lowered to $18 from $20 at H.C. Wainwright
Target:$18.00
+26.4%from $14.24

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance